Business Context and Reporting Period
The supplied filing is Agrify Corporation’s Form 10-Q, not a RYTHM, Inc. filing. It covers the three months ended March 31, 2022, with comparative results for the three months ended March 31, 2021. Agrify develops precision hardware and software grow solutions and provides cultivation, extraction, post-processing, testing, construction, and related services for the cannabis and hemp industries.
Key Financial Metrics
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $26.0 million | $7.0 million |
| Gross profit/(loss) | $4.2 million | $(0.5) million |
| Gross margin | 16.0% | (7.7)% |
| Operating loss | $(9.8) million | $(6.5) million |
| Net loss attributable to Agrify | $(8.9) million | $(3.8) million |
| Loss per share | $(0.36) | $(0.33) |
| Net cash used in operating activities | $(34.2) million | $(7.3) million |
- Revenue increased 271%, primarily from $12.4 million of extraction-solutions revenue following acquisitions and $13.2 million of facility build-out revenue.
- Extraction-solutions revenue generated approximately 33% gross margin, while cultivation-related revenue generated approximately 1% gross margin.
- Operating expenses increased to $13.9 million from $6.0 million, including general and administrative expense of $9.8 million, research and development expense of $2.1 million, and selling and marketing expense of $2.1 million.
- Cash, cash equivalents, and marketable securities totaled $63.4 million at March 31, 2022, plus $30.0 million of restricted cash. Cash and cash equivalents alone were $25.2 million.
- Current assets were $147.5 million and current liabilities were $41.9 million. Inventory increased to $39.0 million from $20.5 million at December 31, 2021.
- Total debt was $67.3 million gross, or $54.1 million net of debt discount, compared with $1.1 million at December 31, 2021. Long-term debt was $51.2 million.
- Loan receivables increased to $34.7 million from $22.3 million, principally reflecting financing provided under the Agrify Total Turn-Key Solution program.
Material Changes Versus the Prior Comparable Period
- Revenue growth reflected the inclusion of extraction businesses acquired in 2021 and Lab Society, acquired February 1, 2022. Lab Society contributed approximately $1.5 million of revenue from acquisition through March 31, 2022.
- Gross profitability improved materially from a gross loss in Q1 2021, but operating and net losses widened because operating expenses grew faster than gross profit.
- Operating cash burn increased substantially, driven primarily by a $16.4 million inventory build, increased prepaid expenses, and additional loans receivable under the TTK program.
- The Company raised approximately $27.3 million gross in a January 2022 private placement of common stock and warrants. The institutional investor also exercised pre-funded warrants in March 2022.
- On March 24, 2022, Agrify completed a $65.0 million senior secured note financing with warrants. The note bears 6.75% cash interest, matures March 1, 2026, and requires monthly amortization beginning February 2023.
- Shares outstanding increased to 26.5 million at March 31, 2022 from 22.2 million at December 31, 2021. Options and warrants represented potential additional dilution; 10.2 million warrants and 3.4 million options were outstanding at quarter-end.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expects full-year gross margin to be in the mid-teens, supported by extraction-equipment sales. It expects meaningful software and production-fee revenue from TTK Solutions to begin in late Q3 or early Q4 2022.
- Management stated that available liquidity, including financing proceeds, was expected to support planned operations for at least the next 12 months. The filing also identifies continued dependence on operating cash generation and access to additional financing.
- The SPA Note contains minimum cash, earnings, and adjusted EBITDA requirements; restrictions on additional debt, liens, investments, and dividends; and an event-of-default redemption price equal to 115% of outstanding principal plus interest.
- The Company has committed approximately $32.9 million to five TTK customers. TTK loan maturities generally occur two to three years after construction completion, with stated interest rates generally ranging from 12% to 18%.
- Supply-chain delays related to COVID-19 have affected some deliveries. Management warns that continued supplier disruption could delay customer deliveries and adversely affect revenue and results.
- The PPP loan balance was approximately $0.8 million and was scheduled to mature in May 2022. Forgiveness remained under SBA review; any unforgiven amount would require repayment.
- Contingent consideration liabilities totaled $7.6 million at March 31, 2022, including $1.4 million recorded for the Lab Society acquisition. Lab Society sellers may receive up to $3.5 million of additional consideration based on 2022 and 2023 revenue.
- The Company is defending litigation brought by former employees involving compensation, equity, employment, fiduciary-duty, and securities-law claims. The filing does not provide a clear quantified exposure.
- Disclosure controls and procedures were not effective as of March 31, 2022 because of previously identified material weaknesses in internal control over financial reporting. Remediation includes additional qualified personnel, documented procedures, and control monitoring.
- The Company reported a non-recurring $0.2 million income-tax benefit related to a partial release of its U.S. valuation allowance following the Lab Society acquisition.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied document identifies Agrify Corporation, ticker AGFY, rather than RYTHM, Inc.
- Review the SPA Note’s financial covenants, minimum-cash requirements, collateral package, amortization schedule, default provisions, and warrant terms.
- Assess whether the Company’s operating cash burn and TTK financing commitments are sustainable as debt amortization begins in 2023.
- Evaluate inventory recoverability, customer collections, and concentration risks, including related-party receivables and TTK loans.
- Review acquisition purchase-price allocations, goodwill and intangible-asset valuations, contingent earn-outs, and potential impairment risk.
- Monitor remediation of the material weaknesses in internal control over financial reporting.
- Review dilution from outstanding options, private-placement warrants, SPA warrants, acquisition shares, and potential earn-out shares.